Aurora cannabis and vectura fertin pharma, inc. announce launch of novel luo cbd lozenge

Launch represents vectura fertin pharma's first medical cannabis cbd lozenge to be introduced in canada launch follows announcement of commercial collaboration between cogent international, a vectura fertin pharma subsidiary, and aurora to leverage aurora's canadian medical cannabis patient platform collaboration will explore the potential to launch vectura fertin pharma's future medical cannabis portfolio in canada edmonton, ab, and stamford, ct – september 9, 2024 - aurora cannabis inc. ("aurora") (nasdaq | tsx: acb), a leading canadian-based global medical cannabis company, and vectura fertin pharma, inc., an innovator in wellness and healthcare, are pleased to announce the launch of the newly developed luo cbd lozenge. the high-quality cbd lozenge was developed by vectura fertin pharma and adheres to stringent safety, quality and regulatory standards to address unmet medical and health needs.
ACB Ratings Summary
ACB Quant Ranking